{
  "denotations": [
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 25,
        "end": 29
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 150,
        "end": 155
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 194,
        "end": 203
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 166,
        "end": 175
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 166,
        "end": 203
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "19884861_11",
  "text": "CONCLUSIONS : Activating EGFR mutations detected in shed DNA in plasma are significantly associated with favorable outcomes in patients with advanced NSCLC receiving docetaxel plus intercalated erlotinib ."
}
